71207-29-9

Basic information

• Product Name: N-hexahydro-4-pyridinylmethyl-N-phenylmethylidenamine
• Synonyms: N-hexahydro-4-pyridinylmethyl-N-phenylmethylidenamine
• CAS NO: 71207-29-9
• Molecular Weight: 202.299
• Mol File: 71207-29-9.mol
• Article Data: 24

Chemical Properties

• CAS DataBase Reference: N-hexahydro-4-pyridinylmethyl-N-phenylmethylidenamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-hexahydro-4-pyridinylmethyl-N-phenylmethylidenamine(71207-29-9)
• EPA Substance Registry System: N-hexahydro-4-pyridinylmethyl-N-phenylmethylidenamine(71207-29-9)

Safety Data

• Hazardous Substances Data: 71207-29-9(Hazardous Substances Data)

Upstream product

• 7144-05-0 4-Aminomethylpiperidine 
• 100-52-7 benzaldehyde 

Downstream Products

• 304905-24-6 N-((1-benzylpiperidin-4-yl)methyl)-1-phenylmethanimine 
• 956722-57-9 1-[1-(2-methoxyethyl)piperidin-4-yl]methanamine 
• 796847-67-1 1-isopropyl-N-[[1-[2-(4-nitrophenyl)ethyl]-4-piperidinyl]methyl]-1H-indazole-3-carboxamide 
• 796847-65-9 C₂₂H₂₅N₅O₃ 

Relevant articles and documents

Hypoxia-Triggered Self-Assembly of Ultrasmall Iron Oxide Nanoparticles to Amplify the Imaging Signal of a Tumor

Hypoxia is a common phenomenon among most solid tumors that significantly influences tumor response toward chemo- and radiotherapy. Understanding the distribution and extent of tumor hypoxia in patients will be very important to provide personalized thera

Piperazine-and piperidine-containing thiazolo[5,4-d]pyrimidine derivatives as new potent and selective adenosine a2a receptor inverse agonists

The therapeutic use of A2A adenosine receptor (AR) antagonists for the treatment of neurodegenerative disorders, such as Parkinson and Alzheimer diseases, is a very promising approach. Moreover, the potential therapeutic role of A2A AR antagonists to avoid both immunoescaping of tumor cells and tumor development is well documented. Herein, we report on the synthesis and biological evaluation of a new set of piperazine-and piperidine-containing 7-amino-2-(furan-2-yl)thiazolo[5,4-d]pyrimidine derivatives designed as human A2A AR antagonists/inverse agonists. Binding and potency data indicated that a good number of potent and selective hA2A AR inverse agonists were found. Amongst them, the 2-(furan-2-yl)-N5-(2-(4-phenylpiperazin-1-yl)ethyl)thiazolo[5,4-d]pyrimidine-5,7-diamine 11 exhibited the highest A2A AR binding affinity (Ki = 8.62 nM) as well as inverse agonist potency (IC50 = 7.42 nM). In addition, bioinformatics prediction using the web tool SwissADME revealed that 8, 11, and 19 possessed good drug-likeness profiles.

Targeting Serotonin 2A and Adrenergic α1 Receptors for Ocular Antihypertensive Agents: Discovery of 3,4-Dihydropyrazino[1,2-b]indazol-1(2H)-one Derivatives

Glaucoma affects millions of people worldwide and causes optic nerve damage and blindness. The elevation of the intraocular pressure (IOP) is the main risk factor associated with this pathology, and decreasing IOP is the key therapeutic target of current pharmacological treatments. As potential ocular hypotensive agents, we studied compounds that act on two receptors (serotonin 2A and adrenergic α1) linked to the regulation of aqueous humour dynamics. Herein we describe the design, synthesis, and pharmacological profiling of a series of novel bicyclic and tricyclic N2-alkyl-indazole-amide derivatives. This study identified a 3,4-dihydropyrazino[1,2-b]indazol-1(2H)-one derivative with potent serotonin 2A receptor antagonism, >100-fold selectivity over other serotonin subtype receptors, and high affinity for the α1 receptor. Moreover, upon local administration, this compound showed superior ocular hypotensive action in vivo relative to the clinically used reference compound timolol.